Impaired immunogenicity of meningococcal neisserial surface protein A in human complement factor H transgenic mice

Infection and Immunity

Volumn 84, Issue 2, 2016, Pages 452-458

  Lujan, Eduardo ^a   Pajon, Rolando ^a,b   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b Labcorp Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; COMPLEMENT FACTOR H; MUTANT PROTEIN; OUTER MEMBRANE PROTEIN; PORIN A; RECOMBINANT NEISSERIAL SURFACE PROTEIN A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; COMPLEMENT FACTOR H, HUMAN; MENINGOCOCCUS VACCINE; NSPA PROTEIN, NEISSERIA; PORIN; PORIN PROTEIN, NEISSERIA;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; COMPLEX FORMATION; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; SERUM BACTERICIDAL ANTIBODY ASSAY; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; FOUNDER EFFECT; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; METABOLISM;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; COMPLEMENT FACTOR H; ESCHERICHIA COLI; FOUNDER EFFECT; HUMANS; IMMUNIZATION; MENINGOCOCCAL VACCINES; MICE, INBRED BALB C; MICE, TRANSGENIC; PORINS; RECOMBINANT PROTEINS; SERUM BACTERICIDAL ANTIBODY ASSAY;

EID: 84957685736     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01267-15     Document Type: Article

References (33)

1. Martin D, Cadieux N, Hamel J, Brodeur BR. 1997. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185:1173-1183. http://dx.doi.org/10.1084/jem.185.7.1173.
2. Cadieux N, Plante M, Rioux CR, Hamel J, Brodeur BR, Martin D. 1999. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun 67:4955-4959.
3. Martin D, Brodeur BR, Hamel J, Couture F, De Alwis U, Lian Z, Martin S, Andrews D, Ellis RW. 2000. Candidate Neisseria meningitidis NspA vaccine. J Biotechnol 83:27-31. http://dx.doi.org/10.1016/S0168-1656(00)00294-7.
4. Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. 1995. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect Immun 63:884-890.
5. Ala'Aldeen DA. 1996. Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. J Med Microbiol 44:237-243. http://dx.doi.org/10.1099/00222615-44-4-237.
6. Danve B, Lissolo L, Mignon M, Dumas P, Colombani S, Schryvers AB, Quentin-Millet MJ. 1993. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 11:1214-1220. http://dx.doi.org/10.1016/0264-410X(93)90045-Y.
7. Danve B, Cadoz M, Lissolo L, Boutry E, Guinet F, Speck D, Nassif X, Quentin-Millet M-J. 1998. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults, p 53. Abstr Eleventh Int Pathogenic Neisserial Conf, Nice, France. http://neisseria.org/ipnc/1998/Abstracts_Neisseria98.pdf.
8. Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, Kimura A, Martin D. 2007. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25:450-457. http://dx.doi.org/10.1016/j.vaccine.2006.08.001.
9. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010 The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6:e1001027. http://dx.doi.org/10.1371/journal.ppat.1001027.
10. Zarantonelli ML, Szatanik M, Giorgini D, Hong E, Huerre M, Guillou F, Alonso JM, Taha MK. 2007. Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect Immun 75:5609-5614 http://dx.doi.org/10.1128/IAI.00781-07.
11. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, GranoffDM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186:3606-3614. http://dx.doi.org/10.4049/jimmunol.1003470.
12. Frandoloso R, Martinez-Martinez S, Calmettes C, Fegan J, Costa E, Curran D, Yu RH, Gutierrez-Martin CB, Rodriguez-Ferri EF, Moraes TF, Schryvers AB. 2015. Nonbinding site-directed mutants of transferrin binding protein B exhibit enhanced immunogenicity and protective capa-bilities. Infect Immun 83:1030-1038. http://dx.doi.org/10.1128/IAI.02572-14.
13. Costa I, Pajon R, GranoffDM. 2014. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. mBio 5:e01625-14. http://dx.doi.org/10.1128/mBio.01625-14.
14. Hou VC, Moe GR, Raad Z, Wuorimaa T, GranoffDM. 2003. Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 71:6844-6849. http://dx.doi.org/10.1128/IAI.71.12.6844-6849.2003.
15. Moe GR, Tan S, GranoffDM. 1999. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 67: 5664-5675.
16. Pajon R, Fergus AM, GranoffDM. 2013. Mutant native outer membrane vesicles combined with a serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa. PLoS One 8:e66536. http://dx.doi.org/10.1371/journal.pone.0066536.
17. Zarantonelli ML, Lancellotti M, Deghmane AE, Giorgini D, Hong E, Ruckly C, Alonso JM, Taha MK. 2008. Hyperinvasive genotypes of Neisseria meningitidis in France. Clin Microbiol Infect 14:467-472. http://dx.doi.org/10.1111/j.1469-0691.2008.01955.x.
18. Zhang MY, Choudhry V, Sidorov IA, Tenev V, Vu BK, Choudhary A, Lu H, Stiegler GM, Katinger HW, Jiang S, Broder CC, Dimitrov DS. 2006 Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 317:21-30. http://dx.doi.org/10.1016/j.jim.2006.09.016.
19. Pajon R, Beernink PT, GranoffDM. 2012. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun 80:2667-2677. http://dx.doi.org/10.1128/IAI.00103-12.
20. Koeberling O, Delany I, GranoffDM. 2011. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 18:736-742. http://dx.doi.org/10.1128/CVI.00542-10.
21. Moe GR, Zuno-Mitchell P, Lee SS, Lucas AH, GranoffDM. 2001. Functional activity of anti-neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun 69:3762-3771. http://dx.doi.org/10.1128/IAI.69.6.3762-3771.2001.
22. Moe GR, Zuno-Mitchell P, Hammond SN, GranoffDM. 2002. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70:6021-6031. http://dx.doi.org/10.1128/IAI.70.11.6021-6031.2002.
23. Giuntini S, Reason DC, GranoffDM. 2011. Complement-mediated bactericidal activity of anti-factorHbinding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79:3751-3759. http://dx.doi.org/10.1128/IAI.05182-11.
24. Vu DM, Wong TT, GranoffDM. 2011. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 29:1968-1973. http://dx.doi.org/10.1016/j.vaccine.2010.12.075.
25. Rossi R, Beernink PT, Giuntini S, GranoffDM. 2015. Susceptibility of meningococcal strains responsible for two serogroup B outbreaks on U.S. university campuses to serum bactericidal activity elicited by the MenB-4C vaccine. Clin Vaccine Immunol 22:1227-1234. http://dx.doi.org/10.1128/CVI.00474-15.
26. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, GranoffDM. 2012 The effect of human factorHon immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog 8:e1002688. http://dx.doi.org/10.1371/journal.ppat.1002688.
27. Koeberling O, Seubert A, GranoffDM. 2008. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198:262-270. http://dx.doi.org/10.1086/589308.
28. GranoffDM, Ram S, Beernink PT. 2013. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? Clin Vaccine Immunol 20:1099-1107. http://dx.doi.org/10.1128/CVI.00260-13.
29. GranoffDM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT. 2015. Binding of complement factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine. J Infect Dis 212: 784-792. http://dx.doi.org/10.1093/infdis/jiv081.
30. Konar M, Rossi R, Walter H, Pajon R, Beernink PT. 2015. A mutant library approach to identify improved meningococcal factor H binding protein vaccine antigens. PLoS One 10:e0128185. http://dx.doi.org/10.1371/journal.pone.0128185.
31. Rossi R, GranoffDM, Beernink PT. 2013. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine 31:5451-5457. http://dx.doi.org/10.1016/j.vaccine.2013.08.099.
32. Koeberling O, Ispasanie E, Hauser J, Rossi O, Pluschke G, Caugant DA, Saul A, Maclennan CA. 2014. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). Vaccine 32:2688-2695. http://dx.doi.org/10.1016/j.vaccine.2014.03.068.
33. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, GranoffDM. 2011. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29:4728-4734 http://dx.doi.org/10.1016/j.vaccine.2011.04.095.